ReviewCureus2025
Leukemias in the Context of Rheumatoid Arthritis: Shared Pathways and Clinical Perspectives.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by systemic inflammation, progressive joint destruction, and increased risk of malignancies, particularly hematological cancers such as leukemias. RA patients appear to have a higher incidence of leukemias, suggesting a possible association between the two conditions. This association is driven by shared pathogenic mechanisms, including chronic inflammation, immune dysregulation, and genetic predispositions. Pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), play a crucial role in sustaining an inflammatory microenvironment that promotes leukemic transformation. Genetic alterations, including mutations in STAT3, TET2, and DNMT3A, further highlight the overlap between RA pathophysiology and hematologic malignancies. Moreover, RA treatments such as methotrexate (MTX), Janus kinase (JAK) inhibitors, and anti-TNF therapies have complex implications, with some studies suggesting potential contributions to leukemia risk through immune suppression and hematopoietic alterations. Clinical implications of this association emphasize the necessity of early detection strategies, biomarker-based risk stratification, and close hematologic monitoring in RA patients. Interdisciplinary collaboration between rheumatologists and hematologists is essential for optimizing treatment approaches while minimizing oncogenic risks. Future research should focus on identifying predictive biomarkers, exploring targeted therapeutic interventions, and elucidating the molecular mechanisms underlying RA-associated leukemias. Advances in multiomics and artificial intelligence-driven risk modeling may facilitate personalized treatment strategies, improving both RA management and leukemia prevention. Given the rising burden of RA and its associated complications, a comprehensive understanding of its link to leukemias is critical for enhancing patient outcomes and guiding clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.